The aim of this study was to assess the serum bactericidal activity (SBA) of levofloxacin compared with that of ofloxacin against methicillin-resistant Staphylococcus aureus (MRSA) isolates. Serum from 10 healthy volunteers (seven females, three males) was collected after a single oral dose of either levofloxacin (500 mg) or ofloxacin (400 mg). Subjects were allocated randomly to treatment after at least a 1 week interval between antibiotic regimens. Three welldefined MRSA strains were tested, each susceptible to levofloxacin and ofloxacin, with different levels of resistance to methicillin (HBD 456, HBD 3 and HBD 2; class 1, 2 and 3 Tomasz heterogeneous resistance, respectively) together with a methicillin-susceptible (MSSA) reference strain (S. aureus ATCC 25923). SBA was tested in vitro by a microtitration method 15 min before dosing and at 1, 4, 8 and 12 h after drug absorption. Levofloxacin was significantly more bactericidal than ofloxacin against all strains of S. aureus tested (SBA 1:2). An SBA was recorded for only a short period with ofloxacin, and thereafter only bacteriostatic activity remained. This study, therefore, confirms the superior activity of levofloxacin over that of ofloxacin against MSSA and MRSA.
Introduction
Staphylococcus aureus continues to be an important cause of both nosocomial and community-acquired infection, 1 particularly in osteomyelitis and endocarditis which require antibiotic therapy for an extended period. Methicillin-resistant S. aureus (MRSA) strains present a significant problem, not least because most MRSA strains are resistant to multiple antibiotics. 2, 3 Levofloxacin, the L-isomer of ofloxacin, is a fluoroquinolone with a broad-spectrum of activity including activity against Gram-positive bacteria. 4 In previous studies, levofloxacin has been shown to be up to four-fold more active in vitro than ofloxacin against staphylococci. 5, 6 Furthermore, levofloxacin has been shown to be effective against both methicillin-susceptible S. aureus (MSSA) and MRSA strains in both in-vitro and in animal tests. 7 In a study of rats with aortic endocarditis, a simulation of oral levofloxacin therapy was at least equivalent to that of standard treatment for MSSA or MRSA endocarditis with either flucloxacillin or vancomycin. 8 Moreover, in a murine model of pyelonephritis, levofloxacin (40 mg/kg od) was shown to be superior to ciprofloxacin (80 mg/kg bd) in preventing pyelonephritis and eradicating MSSA and MRSA. 7 This study was designed to assess the serum bactericidal activity (SBA) of levofloxacin compared with that of ofloxacin against methicillin-resistant fluoroquinolonesusceptible MRSA strains at antibiotic concentrations achieved in human serum.
Materials and methods

Study subjects
Ten healthy volunteers (seven females and three males) were enrolled in this cross-over study. The mean age of the subjects was 28.3 years (range 24-38 years), mean weight 60.2 kg (range 49.5-81 kg) and mean height 167.3 cm (range 158-185 cm). Subjects did not receive any antimicrobial agents for 2 weeks before study drug administration. A medical history, physical examination, and a panel of laboratory tests consisting of serum chemistries, blood cell and platelet counts were performed before and after the study. All relevant laboratory results were normal, and physical examination showed no change during or following completion of the study. The study was approved by the local ethics committee and written informed consent was obtained from each subject.
Administration of the antimicrobial agent
All volunteers received either a single, oral dose of one tablet of levofloxacin 500 mg or two tablets of ofloxacin 200 mg (400 mg). The tablets were swallowed intact with 150 mL of tap water. The regimens were administered in a randomized, cross-over fashion with at least a 1 week interval between antibiotic regimens. Subjects remained fasting for 4 h after drug intake. They then consumed a standard meal and took 300 mL of water.
Serum samples
Blood samples were collected into tubes with no anticoagulant 15 min before and 1, 4, 8 and 12 h after dosing. Samples were frozen immediately after centrifugation and kept at -80°C until the determination of SBA.
Microorganisms and microbiological assays
Three clinical well-defined MRSA strains (kindly provided by Professor Drugeon, Laennec University Hospital, Nantes, France) were used, with different levels of resistance to methicillin: strains HBD 456, HBD 3 and HBD 2 with class 1, 2 and 3 Tomasz heterogeneous resistance, respectively. MSSA ATCC 25923 was used as the reference strain. All strains were susceptible to levofloxacin and ofloxacin. The MICs of the two drugs against each microorganism were determined by a microdilution method as described by the National Committee for Clinical Laboratory Standards.
9 SBA was determined using the microdilution method with dilution performed with a 50:50 ratio of sterile horse serum (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France) and calcium-and magnesiumsupplemented Mueller-Hinton broth (bioMérieux, Marcy l'Etoile, France).
10 Each inoculum was prepared from a 4 h Mueller-Hinton broth culture in a rotary shaker at 37°C, diluted to obtain an inoculum of approximately 10 6 cfu/mL into each well. The microtitre plates were shaken for 15 s on a microshaker, subcultured on Mueller-Hinton agar (bioMérieux) and incubated for 18 h. All assays were performed twice. The serum bactericidal titre (SBT) was defined as the highest dilution of serum showing no growth (Ͼ99.9% reduction of inoculum). Serum taken 15 min before dosing (antibiotic-free sera) was used as a control for testing each organism.
Pharmacodynamic analysis
Calculation of SBA was performed by log-transformation of each reciprocal bactericidal titre. Titres Ͻ1:2 were considered to be 1:1. From the resulting logarithms, means and standard deviation were calculated for each strain as well as for each subject and reconverted to the corresponding reciprocal SBT. The duration of the SBA was defined as the time (h) in which the SBT was у1:2 at any given time.
Statistical analysis
Statistical analysis was performed using the Wilcoxon rank test for paired data for each strain at the different times. A P value Ͻ0.02 was considered significant.
Results
The MICs and MBCs of levofloxacin and ofloxacin against the strains of S. aureus are presented in the Table. Reciprocal mean SBTs versus time for each organism and compound are shown in the Figure. In the samples taken before administration of the antibiotics, no bactericidal activity against S. aureus strains could be measured in the volunteers. Levofloxacin's and ofloxacin's peak SBTs were observed 1 h post-dose in all cases. However, levofloxacin's SBTs were significantly higher than those of ofloxacin at each of the times studied (P Ͻ 0.02). Against MSSA, levofloxacin and ofloxacin peak SBTs reached 1:11 and 1:5, respectively. Against MRSA strains (HBD 456, HBD 3 and HBD 2), the mean peak SBTs for levofloxacin (1:12, 1:5 and 1:9, respectively) were higher than for ofloxacin (1:4, 1:2 and 1:4, respectively). At the trough (12 h post-dose), the levofloxacin SBA was higher than that of ofloxacin. Ofloxacin demonstrated poor or no activity 8 h and 12 h 
Discussion
The antibacterial activity of ofloxacin is known to reside almost entirely within levofloxacin, the L-isomer. 11 In this study, the mean serum concentration of the L-isomer after oral administration was 2.5-fold higher with levofloxacin (500 mg) than with ofloxacin (400 mg) (data not shown). Moreover, levofloxacin was excreted renally with a longer elimination half-life (7 h) in comparison with ofloxacin (5 h). These pharmacodynamic properties probably explain the fact that levofloxacin SBTs were higher than those of ofloxacin for all the strains of S. aureus tested. SBTs also reflect the in-vitro susceptibility of the organism.
Levofloxacin and ofloxacin are more active against S. aureus while ciprofloxacin is more active against Gramnegative bacilli. 4, 5 A number of investigators have determined SBTs after oral administration of ofloxacin or ciprofloxacin. 12, 13 These authors reported that SBTs were low for both drugs for S. aureus. The results of the present study are in agreement with published data for ofloxacin. In addition, ciprofloxacin was found to produce unsatisfactory activity at 4 h (SBTs Ͻ1:2) against S. aureus including after 400 mg single-dose iv administration. 14 Published data indicate that differences in SBTs between organisms primarily reflect differences in MBCs. 15 In our study, the HBD 3 strain had higher MBCs for both levofloxacin and ofloxacin (Table) which could explain the lower SBA observed for this strain.
Serum bactericidal tests have been used as a measure of ongoing therapeutic efficacy for many years 16 and are considered to be a useful prognostic indicator in endocarditis and osteomyelitis. 17, 18 In an attempt to reduce medical costs, patients are being treated as out-patients with longterm oral antibiotics for severe diseases (e.g. osteomyelitis, pyelonephritis, endocarditis). Oral antibiotics can be used after initial iv treatment in sequential or step-down therapy. Levofloxacin is particularly suited to this type of regimen as it is available in both iv and oral formulations. Thus, a patient can continue treatment with the same antibiotic rather than having to change drugs if their initial iv treatment is not available in an oral form. An SBA value of at least 1:8 1 h after drug administration has been demonstrated to correlate with a favourable clinical outcome. 19 Against the fluoroquinolone-susceptible MSSA and HBD 456 and HBD 2 MRSA strains in this study, the SBTs for levofloxacin were у1:8, suggesting that levofloxacin should be effective in treating staphylococcal infections. Levofloxacin has shown clinical efficacy against staphylococcal infections 20 but correlation of clinical efficacy with SBTs needs to be evaluated.
In conclusion, the results of this study confirm the superior activity of levofloxacin against S. aureus in comparison with ofloxacin. Overall, although the SBA was dependent on susceptibility to the fluoroquinolones, it was independent of methicillin-susceptibility. These results suggest that levofloxacin may be useful in the treatment of S. aureus infections.
